Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial Emulation

Documenti analoghi

• Target Trial Emulations of Sodium‐Glucose Cotransporter 2 Inhibitors in Systemic Lupus Erythematosus
  di: Janet Pope, et al.
  Pubblicazione: (2025)
• Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications
  di: Tomás Cerdó, et al.
  Pubblicazione: (2026)
• Reply
  di: Kevin Sheng‐Kai Ma, et al.
  Pubblicazione: (2025)
• Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
  di: Joan T. Merrill, et al.
  Pubblicazione: (2024)
• Aberrant Glycosylation of IgG in Children With Active Lupus Nephritis Alters Podocyte Metabolism and Causes Podocyte Injury
  di: Rhea Bhargava, et al.
  Pubblicazione: (2025)